Saturday, October 3, 2026

USD/JPY Jumps By 1% In The Last 5 Sessions

ViaNews Editorial Team

September 20, 2024

USD/JPY Jumps By 1% In The Last 5 Sessions

(VIANEWS) - USD/JPY (USDJPY) has been up by 1.39% for the last 5 sessions. At 20:06 EST on Thursday, 19 September, USD/JPY (USDJPY) is $142.78.

USD/JPY's yearly highs and lows, it's 2.293% up from its 52-week low and 11.833% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/JPY's Forex is considered to be oversold (<=20).

Previous days news about USD/JPY (USDJPY)

  • Usd/jpy slides further below 142.00 amid softer usd, focus remains on fed decision. According to FXStreet on Wednesday, 18 September, "This, in turn, validates the near-term negative outlook for the USD/JPY pair and supports prospects for an extension of the recent well-established downtrend.", "The USD/JPY pair attracts fresh sellers during the Asian session on Wednesday and slides back below the 142.00 mark in the last hour, eroding a part of the overnight gains and stalling its recovery from the lowest level since July 2023 touched earlier this week. "
  • Usd/jpy: markets are bracing for volatile moves after FOMC – OCBC. According to FXStreet on Wednesday, 18 September, "FOMC decision should see USD/JPY more volatile, OCBC FX analysts Frances Cheung and Christopher Wong note.", "FOMC decision should see USD/JPY trade wild into and post-decision, press conference."
  • Usd/jpy price forecast: slips from 4-day peak, hovers below 142.00. According to FXStreet on Wednesday, 18 September, "The USD/JPY downtrend remains in place, but the Federal Reserve's decision to cut rates by a smaller or larger size could trigger different reactions. ", "If the Fed lowers rates by 25 basis points, this could be bullish for the USD/JPY and push prices toward the September 17 high at 142.47, which, if cleared, will expose the 143.00 figure."

More news about USD/JPY (USDJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com